September 4, 2019 10:10 AM EDT
Financing
Startups

Ver­sant-backed pre­ci­sion on­col­o­gy start­up Re­pare Ther­a­peu­tics scores $82M+ in lat­est round

Natalie Grover

Reporter

More than two years af­ter emerg­ing out of stealth mode with $68 mil­lion and Ver­sant as a found­ing in­vestor, pre­ci­sion on­col­o­gy drug de­vel­op­er Re­pare Ther­a­peu­tics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times